Hainan Huluwa Pharmaceutical Group Co., Ltd.

Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It is active against aerobic Gram-positive cocci (such as Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus, and Pneumococcus), anaerobic Gram-negative rods (such as Bacteroides and Fusobacterium), anaerobic Gram-positive non-spore-forming rods (such as Propionibacterium, Eubacterium, and Actinomyces), and anaerobic and microaerophilic Gram-positive rods (such as Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus).

Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It has antibacterial activity against aerobic Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, and Pneumococcus), anaerobic Gram-negative rods (such as Bacteroides and Fusobacterium), anaerobic Gram-positive non-spore-forming rods (such as Propionibacterium, Eubacterium, and Actinomyces), and anaerobic and microaerophilic Gram-positive rods (such as Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus).

Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It is active against aerobic Gram-positive cocci, anaerobic Gram-negative rods, anaerobic Gram-positive non-spore-forming Bacillus, and anaerobic and microaerophilic Gram-positive rods.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.